Literature DB >> 29363058

Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling.

Gizem Kayki Mutlu1, Ebru Arioglu Inan2, Irem Karaomerlioglu2, V Melih Altan3, Nilgun Yersal4, Petek Korkusuz4, Marcella Rocchetti5, Antonio Zaza5.   

Abstract

β3-Adrenoceptors (AR) stimulate cardiac Na+/K+ pump in healthy hearts. β3-ARs are upregulated by persistent sympathetic hyperactivity; however, their effect on Na+/K+ ATPase activity and ventricular function in this condition is still unknown. Here, we investigate preventive effects of additional β3-AR activation (BRL) on Na+/K+ ATPase activity and in vivo hemodynamics in a model of noradrenaline-induced hypertrophy. Rats received NA or NA plus simultaneously administered BRL in vivo infusion for 14 days; their cardiac function was investigated by left ventricular pressure-volume analysis. Moreover, fibrosis and apoptosis were also assessed histologically. NA induced an hypertrophic pattern, as detected by morphological, histological, and biochemical markers. Additional BRL exposure reversed the hypertrophic pattern and restored Na+/K+ ATPase activity. NA treatment increased systolic function and depressed diastolic function (slowed relaxation). Additional BRL treatment reversed most NA-induced hemodynamic changes. NA decreased Na+/K+ pump α2 subunit expression selectively, a change also reversed by additional BRL treatment. Increasing β3-AR stimulation may prevent the consequences of chronic NA exposure on Na+/K+ pump and in vivo hemodynamics. β3-AR agonism may thus represent a new therapeutic strategy for pharmacological modulation of hypertrophy under conditions of chronically enhanced sympathetic activity.

Entities:  

Keywords:  Hypertrophy; Na+/K+ ATPase; Noradrenaline; β3-Adrenoceptors

Mesh:

Substances:

Year:  2018        PMID: 29363058     DOI: 10.1007/s11010-018-3282-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  48 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent.

Authors:  Bat-Erdene Myagmar; James M Flynn; Patrick M Cowley; Philip M Swigart; Megan D Montgomery; Kevin Thai; Divya Nair; Rumita Gupta; David X Deng; Chihiro Hosoda; Simon Melov; Anthony J Baker; Paul C Simpson
Journal:  Circ Res       Date:  2017-02-20       Impact factor: 17.367

3.  Stimulation of cardiac alpha receptors increases Na/K pump current and decreases gK via a pertussis toxin-sensitive pathway.

Authors:  A Shah; I S Cohen; M R Rosen
Journal:  Biophys J       Date:  1988-08       Impact factor: 4.033

4.  β3-Adrenoceptor-mediated responses in diabetic rat heart.

Authors:  Gizem Kayki-Mutlu; Ebru Arioglu-Inan; Isil Ozakca; Arif T Ozcelikay; Vecdi M Altan
Journal:  Gen Physiol Biophys       Date:  2013-12-13       Impact factor: 1.512

5.  Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart.

Authors:  Zhu-Shan Zhang; Heng-Jie Cheng; Katsuya Onishi; Nobuyuki Ohte; Thomas Wannenburg; Che-Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2005-08-31       Impact factor: 4.030

6.  Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway.

Authors:  T Angelone; E Filice; A M Quintieri; S Imbrogno; A Recchia; E Pulerà; C Mannarino; D Pellegrino; M C Cerra
Journal:  Acta Physiol (Oxf)       Date:  2008-01-17       Impact factor: 6.311

7.  Cardiac responses after norepinephrine-induced ventricular hypertrophy in rats.

Authors:  L Brown; C Sernia; R Newling; P Fletcher
Journal:  J Cardiovasc Pharmacol       Date:  1992-08       Impact factor: 3.105

8.  β3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Atsushi Morimoto; Hiroshi Hasegawa; Qing-Hua Han; William C Little; Che Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-07-19       Impact factor: 4.733

Review 9.  Central sympathetic overactivity: maladies and mechanisms.

Authors:  James P Fisher; Colin N Young; Paul J Fadel
Journal:  Auton Neurosci       Date:  2009-03-06       Impact factor: 3.145

10.  Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling.

Authors:  Nerea Hermida; Lauriane Michel; Hrag Esfahani; Emilie Dubois-Deruy; Joanna Hammond; Caroline Bouzin; Andreas Markl; Henri Colin; Anne Van Steenbergen; Christophe De Meester; Christophe Beauloye; Sandrine Horman; Xiaoke Yin; Manuel Mayr; Jean-Luc Balligand
Journal:  Eur Heart J       Date:  2018-03-07       Impact factor: 29.983

View more
  4 in total

Review 1.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

Review 2.  Androgen Effects on the Adrenergic System of the Vascular, Airway, and Cardiac Myocytes and Their Relevance in Pathological Processes.

Authors:  Abril Carbajal-García; Jorge Reyes-García; Luis M Montaño
Journal:  Int J Endocrinol       Date:  2020-11-12       Impact factor: 3.257

3.  New Progress in Understanding the Cellular Mechanisms of Anti-arrhythmic Drugs.

Authors:  Zhe An; Guang Yang; Xuanxuan Liu; Zhongfan Zhang; Guohui Liu
Journal:  Open Life Sci       Date:  2018-09-22       Impact factor: 0.938

4.  Effects of sitagliptin on ß-adrenoceptor mediated relaxation in streptozotocin-diabetic rat aorta

Authors:  Ayhanım Elif Müderrisoğlu; Betül Rabia Erdoğan; Zeynep Elif Yeşilyurt; Ceren Uyar Boztaş; İrem Karaçömerlioğlu; Vecdi Melih Altan; Ebru Arıoğlu İnan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.